Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma

被引:29
|
作者
Gambichler, Thilo [1 ]
Gnielka, Martha [1 ]
Rueddel, Ines [1 ]
Stockfleth, Eggert [1 ]
Stuecker, Markus [1 ]
Schmitz, Lutz [1 ]
机构
[1] Ruhr Univ Bochum, St Josef Hosp, Dept Dermatol, Skin Canc Ctr, Gudrunstr 56, D-44791 Bochum, Germany
关键词
PD-L1; Keratoacanthoma; Actinic keratosis; Bowen's disease; Squamous cell carcinoma; Tumour-infiltrating lymphocyte; LUNG-CANCER; PEMBROLIZUMAB; ASSOCIATION; INHIBITOR; RISK;
D O I
10.1007/s00262-017-2015-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Programmed cell death 1 (PD-1) and its ligands (PD-L1) play a major role in the immune responses of a variety of cancers. Objectives To investigate the expression of PD-L1 in different progression forms of cutaneous squamous cell carcinoma (cSCC) and keratoacanthoma (KA). Methods We performed immunohistochemical staining of 21 KA, 26 actinic keratoses (AK), 20 Bowen's diseases (BD), and 26 high-risk cSCC. The staining patterns were assessed using the tumour proportion score and staining intensity evaluation. Immunohistology scores were statistically analysed. Results PD-L1 expression of tumour cells as well as tumour-infiltrating cells (TILs) was significantly higher in KA and cSCC when compared to AK and BD (P = 0.00028 and P = 0.00033, respectively). We observed a very strong positive correlation between the PD-L1 protein expression of tumour cells of KA and the PD-L1 protein expression of TILs (r = 0.97; P < 0.0001). A similar correlation was also found for cSCC (r = 0.86; P < 0.0001). The percentage of PD-L1 + tumours was 33.3% for KA and 26.9% for cSCC. Similarly, the percentage of PD-L1 + TILs in KA and cSCC was 33.3 and 34.6%, respectively. Conclusions PD-L1 is differently expressed in cSCC and closely related non-melanoma skin cancer. cSCC exhibit PD-L1 expression in a fourth of cases, indicating that PD1/PD-L1 inhibitors might be beneficial in a proportion of patients with an inoperable or metastatic cSCC. Unlike AK and BD, TILs and tumour cells of KA and cSCC present very similar PD-L1 expression profiles indicating a common immune escape mechanism.
引用
收藏
页码:1199 / 1204
页数:6
相关论文
共 50 条
  • [21] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Delafoy, Alice
    Uguen, Arnaud
    Lemasson, Gilles
    Conan-Charlet, Virginie
    Pradier, Olivier
    Lucia, Francois
    Schick, Ulrike
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (01) : 343 - 351
  • [22] PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component
    Tanigawa, Masahiko
    Naito, Yoshiki
    Akiba, Jun
    Kawahara, Akihiko
    Okabe, Yoshinobu
    Ishida, Yusuke
    Ishikawa, Hiroto
    Hisaka, Toru
    Fujita, Fumihiko
    Yasunaga, Masafumi
    Shigaki, Takahiro
    Sudo, Tomoya
    Mihara, Yutaro
    Nakayama, Masamichi
    Kondo, Reiichiro
    Kusano, Hironori
    Shimamatsu, Kazuhide
    Okuda, Koji
    Akagi, Yoshito
    Yano, Hirohisa
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2069 - 2074
  • [23] Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
    Ritprajak, Patcharee
    Azuma, Miyuki
    ORAL ONCOLOGY, 2015, 51 (03) : 221 - 228
  • [24] Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
    Jiang, Dongxian
    Song, Qi
    Wang, Haixing
    Huang, Jie
    Wang, Hao
    Hou, Jun
    Li, Xiaojing
    Xu, Yifan
    Sujie, Akesu
    Zeng, Haiying
    Tan, Lijie
    Hou, Yingyong
    ONCOTARGET, 2017, 8 (05) : 8315 - 8329
  • [25] Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
    Ribbat-Idel, Julika
    Dressler, Franz F.
    Krupar, Rosemarie
    Watermann, Christian
    Paulsen, Finn-Ole
    Kuppler, Patrick
    Klapper, Luise
    Offermann, Anne
    Wollenberg, Barbara
    Rades, Dirk
    Laban, Simon
    Reischl, Markus
    Bruchhage, Karl-Ludwig
    Idel, Christian
    Perner, Sven
    FRONTIERS IN MEDICINE, 2021, 8
  • [26] Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
    Bill, Ruben
    Faquin, William C.
    Pai, Sara I.
    HEAD & NECK PATHOLOGY, 2023, 17 (04) : 969 - 975
  • [27] Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
    Heeren, A. Marijne
    Punt, Simone
    Bleeker, Maaike C. G.
    Gaarenstroom, Katja N.
    van der Velden, Jacobus
    Kenter, Gemma G.
    de Gruijl, Tanja D.
    Jordanova, Ekaterina S.
    MODERN PATHOLOGY, 2016, 29 (07) : 753 - 763
  • [28] Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma
    Deng, Chuangzhong
    Li, Zaishang
    Guo, Shengjie
    Chen, Peng
    Chen, Xiaofeng
    Zhou, Qianghua
    Chen, Jieping
    Yu, Xingsu
    Wu, Xiaoliang
    Ma, Wenjuan
    Xie, Qiankun
    Ye, Yunlin
    Li, Yonghong
    Qin, Zike
    Liu, Zhuowei
    Liu, Ranyi
    Zhang, Zhenfeng
    Yao, Kai
    Han, Hui
    Zhou, Fangjian
    ONCOIMMUNOLOGY, 2017, 6 (02):
  • [29] PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule
    Vital, Domenic
    Holzmann, David
    Huber, Gerhard F.
    Moch, Holger
    Morand, Gregoire B.
    Ikenberg, Kristian
    RHINOLOGY, 2018, 56 (03) : 255 - 260
  • [30] CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
    Nishida, Haruto
    Kondo, Yoshihiko
    Kusaba, Takahiro
    Kawamura, Kazuhiro
    Oyama, Yuzo
    Daa, Tsutomu
    PLOS ONE, 2023, 18 (02):